AC Immune's Parkinson's Vaccine Hits All Primary Endpoints in Phase 2 Part 1
ACIU sits 30% above its 52-week low of $2.095 on light trading volume (0.4× avg).
Summary
AC Immune reported positive Week-100 safety and immunogenicity data from Part 1 of its VacSYN Phase 2 trial for ACI-7104, a Parkinson's disease immunotherapy. All primary endpoints were met, confirming the vaccine's ability to generate a strong immune response with an acceptable safety profile. This follows the FDA's Fast Track designation and IND clearance for ACI-7104 in August, and the company now plans to discuss the development path with the FDA in early 2027. The data de-risks the program and supports advancement to later-stage trials, a meaningful step for a company with a market cap under $300 million. Investors will watch for the FDA meeting outcome and any partnership or funding announcements to support the next phase.
At the time of this announcement, ACIU was trading at $2.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $277.8M. The 52-week trading range was $2.10 to $4.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.